Capecitabine in treating patients with advanced, persistent, or recurrent cervical cancer: an active and safe option?

Federica Tomao, Giuseppe Caruso, Lucia Musacchio, Violante Di Donato, Maria Cristina Petrella, Monica Verrico, Silverio Tomao, Pierluigi Benedetti Panici, Ludovico Muzii, Innocenza Palaia

Research output: Contribution to journalArticlepeer-review


Introduction: Advanced, persistent or recurrent cervical cancer in patients not amenable to curative surgery or radiotherapy predicts a dismal prognosis. Systemic chemotherapy based on paclitaxel/cisplatin ± bevacizumab is the current standard of care. However, once progression occurs, the possibility of alternative treatment options is very limited.Areas covered: The usefulness of capecitabine has been well-established against several cancer types, including head and neck, breast, and colorectal cancer. This review covers current literature evidence on the clinical efficacy and safety of capecitabine in cervical cancer treatment, either as monotherapy or combined with other agents or chemo-radiotherapy.Expert opinion: Recent clinical data, albeit scant, suggested a promising role for capecitabine both as monotherapy in patients with platinum-resistant cervical cancer and in combination with cisplatin in chemotherapy-naïve patients with metastatic or recurrent cervical cancer. In our opinion, capecitabine, especially in combination regimens, could represent a valid treatment option and further research is warranted to better understand its effectiveness in these challenging patients.

Original languageEnglish
Pages (from-to)641-650
Number of pages10
JournalExpert Opinion on Drug Safety
Issue number6
Publication statusPublished - Jun 2021


  • Antimetabolites, Antineoplastic/administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols/administration & dosage
  • Capecitabine/administration & dosage
  • Combined Modality Therapy
  • Female
  • Humans
  • Neoplasm Recurrence, Local
  • Uterine Cervical Neoplasms/drug therapy


Dive into the research topics of 'Capecitabine in treating patients with advanced, persistent, or recurrent cervical cancer: an active and safe option?'. Together they form a unique fingerprint.

Cite this